Pharmaceuticals
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company") , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...
2021-10-21 15:58
1315
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE
SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was official...
2021-10-21 10:31
2392
GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...
2021-10-21 08:05
1799
EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization
CHICAGO and KANSAS CITY, Mo., Oct. 20, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, andIntouch Group®, a full-service global agency network serving the pharmaceutical industry, today announced that they signed an agreemen...
2021-10-20 22:34
3355
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen va...
2021-10-20 21:24
4335
Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference
* Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. * Statistically significant 114% faster time to reach EQ-5D-5L Q6 ≥ 90% versus SOC/best supportive care. * Statistically significant 57% faster time to norm...
2021-10-20 20:52
1806
Island Pharmaceuticals to discuss its potential dengue fever preventative at Pharma Meeting Brazil & Latam 2021
MELBOURNE, Australia, Oct. 20, 2021 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to be attending Pharma Meeting Brazil & Latam 2021, this week and presenting to potential partners. Island's attendance at the co...
2021-10-20 18:00
1751
Xinhua Silk Road: 52nd Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi
BEIJING, Oct. 20, 2021 /PRNewswire/ -- The 52nd Zhangshu National Traditional
Chinese Materia MedicaTrade
2021-10-20 17:27
2505
Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources
Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines SEATTLE, Oct. 20, 2021 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today a comm...
2021-10-20 13:29
2067
CStone received China NMPA IND acceptance for lorlatinib in Chinese patients with ROS1-positive advanced NSCLC
SUZHOU, China, Oct. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that the investigational new drug (...
2021-10-20 08:00
3008
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...
2021-10-20 05:08
1664
Excelra Announces Addition of Sudip Nandy to its Board of Directors
HYDERABAD, India, Oct. 19, 2021 /PRNewswire/ -- Excelra, a leading Data and Analytics provider for Life Science organizations, announced the appointment of Sudip Nandy to the company's board of directors effective 1st October 2021. Mr. Nandy is an acclaimed business leader with over 30 years of e...
2021-10-19 21:00
6191
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
BEIJING, Oct. 19, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189, which is the company's...
2021-10-19 12:56
1732
CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections
LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
2021-10-19 09:00
1687
Australian businesses invited to advance the future of healthcare technologies in the Medtronic APAC Innovation Challenge
SYDNEY, Oct. 19, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in healthcare technology, invites Australian businesses to participate in the newly launchedMedtronic APAC Innovation Challenge (MAIC). Providing an opportunity for innovators in the region to pitch and advance the...
2021-10-19 06:51
3063
The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics
SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a research team led by Prof. Shaomeng Wang, ...
2021-10-18 22:42
2751
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...
2021-10-18 20:00
1568
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-10-18 08:00
4030
AFT Launches NZ-Made, 100% Natural, 90% Recyclable Hemptuary® Skincare Range
SYDNEY, Oct. 18, 2021 /PRNewswire/ -- Skincare mavens and beauty gurus have a
new product to not only feel good in but feel good about – AFT Pharmaceuticals'
new skincare range, Hemptuary®, is made inNew Zealand from 100% natural
ingredients and has packaging that is 90% recyclable.
2021-10-18 05:00
1751
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...
2021-10-15 12:44
1677
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 273 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
13075
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9154
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8279
